RecruitingNot ApplicableNCT06114108

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Phase III Randomized Controlled Trial Comparing Maintenance Systemic Therapy Alone With Systemic Therapy Plus Local Ablative Treatment for Patients With Advanced Stage IV Non-small Cell Lung Cancer

Sponsor

Swiss Cancer Institute

Enrollment

128 participants

Start Date

Dec 21, 2023

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer (NSCLC)Stage IV

Summary

Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases. The current standard of care therapy at this advanced stage of lung cancer includes systemic anti-cancer therapy such as chemotherapy, immunotherapy to boost the body's immune response, or targeted therapy that directly hinders tumor growth. In this study, the aim is to find out whether it is better if, after a good response to the standard therapy, the remains of main tumor and the metastases are additionally treated by surgery and/or radiation.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial tests whether adding a focused, local treatment (such as radiation or ablation) to standard systemic therapy (like chemotherapy or immunotherapy) helps patients with stage IV non-small cell lung cancer live longer or better. Systemic therapy treats the whole body; local treatment targets specific tumor spots. **You may be eligible if:** - You are 18 or older - You have confirmed stage IV non-small cell lung cancer (NSCLC) - You are currently responding to or stable on first-line systemic treatment - You have a limited number of sites where the cancer has spread **You may NOT be eligible if:** - Your cancer has spread too widely for local treatment to be feasible - You have progressed or failed on first-line treatment - You have major health conditions that prevent safe participation - You had more than one metastasis surgically removed before trial entry Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSystemic therapy alone or in combination with LAT (surgery and/or radiotherapy)

The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.

OTHERSurgery

Surgery

RADIATIONRadiotherapy

Radiotherapy